Hematologic complications of anti-CMV therapy in solid organ transplant recipients.
Cytomegalovirus (CMV) infection complicates the post-operative course of patients receiving solid organ transplants. While ganciclovir has significantly reduced the direct effects of CMV infection, some patients cannot tolerate the optimal therapeutic exposure required for CMV prevention and treatment. Few reports directly address the incidence, consequences, and risk factors for hematologic toxicities related to ganciclovir therapy. Nevertheless, leukopenia, thrombocytopenia, and anemia occur in 5-50% of patients. Current strategies, focused on ganciclovir dose reduction, may increase the risk of CMV reactivation and drug-resistant disease. The current article reviews the incidence, risk factors, and consequences of ganciclovir-associated hematologic adverse events in transplant recipients. Management strategies, including ganciclovir dose reduction, and the addition of CMV hyperimmune globulin are discussed. Exposing this relatively frequently occurring, but uncommonly discussed, toxicity should lead to better avoidance and treatment strategies, without placing patients at increased risk of CMV disease.
Danziger-Isakov
Lara
L
Center for Pediatric Infectious Diseases, The Children's Hospital at Cleveland Clinic, Cleveland, OH, USA. danzigl@ccf.org
Mark Baillie
G
G
D000998:Antiviral Agents / Q000009:adverse effects*; D003586:Cytomegalovirus Infections / Q000517:prevention & control*; D006801:Humans; D007136:Immunoglobulins / Q000627:therapeutic use; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors / Q000627:therapeutic use; D009503:Neutropenia / Q000139:chemically induced*; D019737:Transplants / Q000821:virology*
D000998:Antiviral Agents; D007136:Immunoglobulins; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; C045781:cytomegalovirus-specific hyperimmune globulin